The Prevalence and Importance of Variant Patterns in Nodular Lymphocyte Predominant Hodgkin Lymphoma

• Badr AbdullGaffar

  Pathology section, Rashid hospital, Oud Metha Road, Dubai, United Arab Emirates

 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare type of B-cell lymphoma with good prognosis and distinct clinicopathologic features. The hallmark histological feature is the presence of malignant lymphocyte predominant (LP) cells embedded within nodules predominantly composed of small B-lymphocytes. Immunoarchitectural variations from these classic nodules could occur. The clinical and pathological significance of NLPHL with variant patterns is, however, uncertain and controversial. Some oncologists and pathologists consider variant atypical nodules to represent a simple localized overgrowth of the LP cells without significant pathological or clinical implications. Other oncologists, however, suggest that they might represent a different biological behavior in the form of intranodal progression with early transformation into large B-cell lymphoma. Therefore, NLPHLs with variant atypical patterns represent a more aggressive clinical course and an indicator of a higher risk of recurrence that warrants a more aggressive treatment even in the early stages.

We performed a retrospective review study to investigate the prevalence and importance of atypical nodules in NLPHL. We found seven cases of NLPHL, three (43%) of which showed variant patterns with different immunoarchitectural features from the classic nodules of NLPHL. We did not find clinical or prognostic differences between the two groups of classic nodules of NLPHL and atypical variant nodules of NLPHL. The significance of which, however, cannot be drawn from this small case series. Therefore, further larger scale studies are warranted. In addition, pathologists should be aware of this phenomenon to avoid overcalling these cases as high-grade lymphomas.

Poppema S, Delsol G, Pileri SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma, in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 4th ed, 2008, pp. 323-325.

Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102: 3753-58. http://dx.doi.org/10.1182/blood-2003-02-0626

Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008; 205: 2251-68. http://dx.doi.org/10.1084/jem.20080809

Fanale MA, Younes A. Nodular lymphocyte predominant Hodgkin’s lymphoma. Cancer Treat Res 2008; 142: 367-81.

Greiner TC, Gascoyne RD, Anderson ME, et al. Nodular lymphocyte-predominant Hodgkin’s disease associated with large-cell lymphoma: analysis of Ig gene rearrangement by V-J polymerase chain reaction. Blood 1996; 88: 657-66.

Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2003; 44: 1903-10. http://dx.doi.org/10.1080/1042819031000123528

Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27: 1346-56. http://dx.doi.org/10.1097/00000478-200310000-00007

Nguyen PL, Ferry JA, Harris NL. Progressive transformation of germinal centers and nodular lymphocyte predominant Hodgkin’s disease, a comparative immunohistochemical study. Am J Surg Pathol 1999; 23: 27-33. http://dx.doi.org/10.1097/00000478-199901000-00003

Unal A, Sari I, Deniz K, et al. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lympoma 2005; 46: 1613-17. http://dx.doi.org/10.1080/10428190500236502

• PDF